The past decade has been a game-changing one for Vertex Pharmaceuticals (NASDAQ: VRTX). The biotech won approval for its ...

Pacira BioSciences, Inc.'s stock is up 33%, backed by a new Exparel patent, growth strategies, and market trends. Click here ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

collecting approvals for a gene-editing therapy for blood disorders a little over a year ago and a pain treatment just recently. Vertex's portfolio of CF drugs has fueled earnings performance over ...

On top of this, one program in particular could supercharge Vertex's revenue over the next 10 years. It focuses on a very common problem that has limited treatment options: pain. Today's over-the ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

NY resident Sebastien Beauzile was treated with a pioneering new gene therapy approach called Lyfgenia, curing his sickle ...

Collegium Pharmaceutical is executing on commercializing its drugs and growing sales. Click here to find out why COLL stock ...

Vertex Pharma could be close to succeeding in the long-standing quest to find an alternative to potentially addictive opioids for the treatment of pain associated with common medical procedures.

This drug may reduce the risk of addiction to pain medications by decreasing reliance on opioids to reduce pain.